EGFR and non-small cell lung carcinoma: We observed a much better ORR (38.1% vs. 18.2%) and significant PFS benefit (median, 7.73 vs. 5.93 months, HR = 0.60, p = 0.014) of C + A compared with chemotherapy alone, which was much similar to that reported in our previous nationwide study, indicating a median PFS of 7.5 and 5.6 months respectively for NSCLC patients with EGFR ex20ins.8